8-K: 4D Molecular Therapeutics Issues Pre-Funded Warrants

4D Molecular Therapeutics exchanged common stock for pre-funded warrants with key institutional investors, adjusting its capital structure.

Summary

• 4D Molecular Therapeutics, Inc. (FDMT) entered into exchange agreements with RA Capital Healthcare Fund, L.P. and Biotechnology Value Fund, L.P. and its affiliates (BVF).
• RA Capital exchanged 4,850,000 shares of common stock for a pre-funded warrant to acquire 4,850,000 shares of the company's common stock.
• BVF exchanged 1,750,000 shares of common stock for a pre-funded warrant to acquire 1,750,000 shares of the company's common stock.
• The pre-funded warrants have an exercise price of $0.0001 per underlying share of common stock, are immediately exercisable, and do not expire until fully exercised.
• As of January 23, 2026, the company had 51,007,874 shares of common stock outstanding.
• This outstanding share count does not include 16,935,665 shares of common stock issuable upon the exercise of all pre-funded warrants outstanding as of January 23, 2026.
• The warrants include a beneficial ownership blocker, preventing exercise if it would cause the holder's aggregate beneficial ownership to exceed 4.99% or 9.99% of the total outstanding common stock.
• The pre-funded warrants were issued without registration in reliance on the exemption from registration contained in Section 3(a)(9) of the Securities Act of 1933.

Sentiment

Score: 6

Explanation: The transaction is a neutral to slightly positive technical adjustment to the capital structure, primarily aimed at managing beneficial ownership for significant investors. It does not reflect operational performance or new capital infusion but rather a restructuring of existing equity holdings.

Positives

• Provides flexibility for large institutional investors (RA Capital, BVF) to manage their beneficial ownership percentages without triggering certain reporting requirements under Section 13(d) of the Exchange Act.
• Allows the company to maintain relationships with significant investors while potentially optimizing its capital structure.
• The warrants are immediately exercisable, providing liquidity options for holders.

Negatives

• While the shares were already held by these investors, the conversion to warrants means they are still a source of potential future dilution upon exercise, even if the exercise price is nominal.
• The existence of a large number of outstanding warrants (16,935,665 shares potentially issuable) could create an overhang on the stock, potentially impacting market perception.

Risks

• Dilution Risk: The exercise of the pre-funded warrants, although at a nominal price, will increase the number of outstanding common shares, potentially diluting the ownership percentage of existing shareholders.
• Market Overhang: The significant number of shares underlying the warrants (16,935,665 shares) could create a perception of future selling pressure, even if the shares were previously outstanding.
• Regulatory Compliance: The beneficial ownership blocker is critical for compliance with Section 13(d) of the Exchange Act, and any miscalculation or change in interpretation could have implications.

Future Outlook

The pre-funded warrants are exercisable at any time until fully exercised and do not expire, providing long-term flexibility for the holders to convert them into common stock, subject to beneficial ownership limitations.

Industry Context

This type of transaction, involving the exchange of common stock for pre-funded warrants with beneficial ownership blockers, is a common strategy employed by publicly traded companies, particularly in the biotechnology sector, to manage the holdings of large institutional investors. It allows investors to maintain their economic interest and exposure to the company's stock while staying below certain beneficial ownership thresholds (e.g., 5% or 10%) that would trigger more extensive public reporting requirements under Section 13(d) of the Exchange Act. This can be beneficial for both the company and the investors by reducing administrative burden and potential market speculation related to large stake disclosures.

Comparison to Industry Standards

• This transaction aligns with standard practices for managing large institutional investor positions. Companies like Moderna (MRNA) or BioNTech (BNTX) have utilized similar structures in the past to accommodate significant investments while navigating regulatory beneficial ownership reporting thresholds.
• The specific 4.99% or 9.99% beneficial ownership blocker is a common threshold used to avoid triggering Schedule 13D filing requirements, which mandate more detailed and frequent disclosures from investors holding over 5% of a company's stock with an intent to influence management.
• The nominal exercise price ($0.0001) is typical for pre-funded warrants, making them economically equivalent to common stock but with the added structural benefit of the blocker.

Corporate Governance

Related Party Transactions

• The exchange agreements were made with RA Capital Healthcare Fund, L.P. and Biotechnology Value Fund, L.P. and its affiliates (BVF), which are significant institutional investors in the company.

Stakeholder Impact

• Shareholders: Potential for future dilution upon warrant exercise, though the underlying shares were already held by these investors. The transaction aims to manage large investor positions, which can be seen as a governance positive.
• Institutional Investors (RA Capital, BVF): Provides flexibility in managing their beneficial ownership percentages, avoiding certain regulatory reporting thresholds while maintaining their economic exposure to the company.

Next Steps

• Holders of the pre-funded warrants may exercise them at any time, subject to beneficial ownership limitations.
• The company will continue to manage its capital structure and investor relations.

Key Dates

Recommendation

This filing describes a technical capital structure adjustment, specifically an exchange of common stock for pre-funded warrants with existing large investors. It does not introduce new capital, reflect operational performance, or signal a fundamental change in the company's business prospects. Therefore, it is unlikely to significantly alter the investment thesis for a seasoned investor, warranting a 'hold' recommendation as it maintains the status quo regarding the economic exposure of these investors while adjusting their reporting obligations.

Keywords

4D Molecular Therapeutics, FDMT, pre-funded warrants, common stock, equity exchange, capital structure, beneficial ownership, Section 13(d), SEC 8-K, institutional investors, RA Capital, BVF, dilution